| __timestamp | Travere Therapeutics, Inc. | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 59644696 | 381287000 |
| Thursday, January 1, 2015 | 79541000 | 452612000 |
| Friday, January 1, 2016 | 98015000 | 316800000 |
| Sunday, January 1, 2017 | 103958000 | 330100000 |
| Monday, January 1, 2018 | 103654000 | 265800000 |
| Tuesday, January 1, 2019 | 128951000 | 336200000 |
| Wednesday, January 1, 2020 | 135799000 | 423900000 |
| Friday, January 1, 2021 | 149883000 | 467000000 |
| Saturday, January 1, 2022 | 220206000 | 487000000 |
| Sunday, January 1, 2023 | 265542000 | 477100000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, United Therapeutics consistently outspent Travere, with SG&A expenses peaking at approximately 487 million in 2022. In contrast, Travere's expenses grew significantly, more than quadrupling from 2014 to 2023, reaching around 266 million. This trend highlights Travere's aggressive expansion strategy, while United Therapeutics maintains a steady financial approach. The data suggests a strategic divergence, with Travere focusing on rapid growth and United Therapeutics prioritizing stability. These insights provide a window into the evolving dynamics of the pharmaceutical sector, offering valuable lessons for investors and industry analysts alike.
Gilead Sciences, Inc. vs United Therapeutics Corporation: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
United Therapeutics Corporation and Bio-Techne Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Catalyst Pharmaceuticals, Inc.
Comparing SG&A Expenses: United Therapeutics Corporation vs Bausch Health Companies Inc. Trends and Insights
United Therapeutics Corporation vs Vericel Corporation: SG&A Expense Trends
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Incyte Corporation or Travere Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Veracyte, Inc. and Travere Therapeutics, Inc.
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.